e-Drug3D

1603

CANAGLIFLOZIN

INN
CANAGLIFLOZIN

cas 842133-18-0

CLASS

METABOLISM
TYPE 2 DIABETES MELLITUS
SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITOR

ROUTE (list)

ORAL

ATC code

A10BK02
A10BD16

PK parameters

F 65 PERCENT
VD 119 LITER
Cl 11.5 LITER / HOUR
PPB 99 PERCENT
t1/2 13.1 HOUR

Solubility

PRACTICALLY INSOLUBLE IN WATER FROM PH 1.1 TO 12.9

Target

TARGET SODIUM-GLUCOSE CO-TRANSPORTER 2 (SGLT2)

PDB
8HDH (STRUCTURE OF HUMAN SGLT2-MAP17 COMPLEX WITH CANAGLIFLOZIN)

Ligand code = L3R (link to the list of PDB complexes)

Download experimental 3D coordinates of L3R with added hydrogens

DrugCentral

Sodium,glucose cotransporter 2 UNIPROT P31639 SLC5A2

Download SDF file

D-Glucitol, 1,5-anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-, (1S)-

Formula:
C24H25FO5S

Calculated chemical properties:

MW 444.51
NB_atoms 31
XLogP 2.97
PSA 91.134
NB_HD 4
NB_HA 5
fsp3 0.33
Lipinski(0=no;1=yes) 1

FDA
NDA 204042 (label) INN (CANAGLIFLOZIN) INVOKANA (JANSSEN PHARMS) APPROVAL= AP YEAR= 2013
NDA 204353 (label) INN (CANAGLIFLOZIN ; METFORMIN HYDROCHLORIDE) INVOKAMET (JANSSEN PHARMS) APPROVAL= AP YEAR= 2014
NDA 205879 (label) INN (CANAGLIFLOZIN ; METFORMIN HYDROCHLORIDE) INVOKAMET XR (JANSSEN PHARMS) APPROVAL= AP YEAR= 2016
NDA 210297 (pdf not found) INN (CANAGLIFLOZIN) CANAGLIFLOZIN (SANDOZ INC) APPROVAL= TA YEAR= 2020
NDA 210451 (pdf not found) INN (CANAGLIFLOZIN) CANAGLIFLOZIN (TEVA PHARMS USA) APPROVAL= TA YEAR= 2022
NDA 210503 (pdf not found) INN (CANAGLIFLOZIN) CANAGLIFLOZIN (LAURUS LABS LTD) APPROVAL= TA YEAR= 2022
NDA 210541 (pdf not found) INN (CANAGLIFLOZIN) CANAGLIFLOZIN (ZYDUS PHARMS USA INC) APPROVAL= TA YEAR= 2023
NDA 210542 (pdf not found) INN (CANAGLIFLOZIN ; METFORMIN HYDROCHLORIDE) CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE (ZYDUS PHARMS USA INC) APPROVAL= TA YEAR= 2023